Purity>90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAE)
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175479-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $139.90 | |
| Ab175479-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $699.90 | |
| Ab175479-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,069.90 | |
| Ab175479-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,799.90 |
Purity>90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAE)
| Product Name | Brentuximab vedotin (anti-CD30) - Primary antibody, specific to TNFRSF8, >90% (SDS-PAGE&SEC), high purity, Human IgG1 |
|---|---|
| Synonyms | CD 30 antibody | CD30 antibody | CD30 antigen antibody | CD30L receptor antibody | Cytokine receptor CD30 antibody | D1S166E antibody | KI 1 antibody | KI 1 antigen antibody | Ki-1 antigen antibody | KI1 antibody | Lymphocyte activation antigen CD30 antib |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥90%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | TNFRSF8 |
| Conjugation | MC-VC-PAB-MMAE |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of CD30 |
| Product Description | Brentuximab vedotin (anti-CD30) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin (anti-CD30) can be used for the research of relapsed and refractory Hodgkin lymphoma. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145.48 kDa |
| Purification Method | Protein A purified |
| Purity | >90% (SDS-PAGE&SEC) |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 914088-09-8 |
Brentuximab vedotin (anti-CD30) (Ab175479) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling CD30 (red) with Brentuximab vedotin (anti-CD30) (Ab175479). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Brentuximab vedotin (anti-CD30) (Ab175479) - Flow Cytometry
Flow Cytometry analysis of K562 cells labelling CD30 (red) with Brentuximab vedotin (anti-CD30) (Ab175479). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Brentuximab vedotin (anti-CD30) (Ab175479) - ELISA
Immobilized Recombinant Human CD30 protein (rp169577) at 1.0 μg/mL can bind Brentuximab vedotin (anti-CD30) (Ab175479) with the EC50 of 84.31 ng/mL.
Brentuximab vedotin (anti-CD30) (Ab175479) - SEC
The purity of Brentuximab vedotin (anti-CD30) (Ab175479) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| IMGT/mAb-DB | 324 |
|---|---|
| Wikipedia | Brentuximab_vedotin |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0606931 | Certificate of Analysis | Jun 18, 2024 | Ab175479 |
| ZJ24F0606930 | Certificate of Analysis | Jun 18, 2024 | Ab175479 |
| ZJ24F0606929 | Certificate of Analysis | Jun 18, 2024 | Ab175479 |
| 1. Mitra A, Sept D. (2004) Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.. Biochemistry, 43 (44): (13955-62). [PMID:15518544] |
| 2. Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.. Lancet Oncol, 14 (13): (1348-56). [PMID:24239220] |
| 3. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A et al.. (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet, 385 (9980): (1853-62). [PMID:25796459] |
| 4. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M et al.. (2018) Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.. N Engl J Med, 378 (4): (331-344). [PMID:29224502] |
| 5. Bowen MA, Olsen KJ, Cheng L, Avila D, Podack ER. (1993) Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation.. J Immunol, 151 (11): (5896-906). [PMID:8245437] |
